{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T19:20:27Z","timestamp":1773170427689,"version":"3.50.1"},"reference-count":62,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2019,11,6]],"date-time":"2019-11-06T00:00:00Z","timestamp":1572998400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title\/>\n                  <jats:p>Oncologic treatment is being revolutionized by a burgeoning number of immune checkpoint inhibitors (ICPis). To date, seven ICPis have received Food and Drug Administration approval, targeting cytotoxic T-lymphocyte antigen, programmed cell death, or programmed cell death ligand. Adverse events associated with checkpoint inhibition have been described in the literature. Guidelines exist for the most common of these, but as the use of ICPis becomes more common, the number of patients presenting with rare events will increase. This article reviews the diagnosis and management of rare ocular, hematological, luminal gastrointestinal, and rheumatological toxicities arising from ICPi treatment.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Key Points<\/jats:title>\n                  <jats:p>As the use of immune checkpoint inhibitors (ICPis) becomes more common, the number of rare immune-related adverse events (irAEs) will increase. A high level of suspicion is required to identify and treat these toxicities. Although it can be difficult to definitively attribute rare irAEs to ICPis, a temporal and mechanistic relationship and the absence of other etiologies should make the treating physician suspicious for a rare irAE. Certain rare irAEs, such as celiac disease, do not require treatment with glucocorticoids. Thus, differentiating this irAE from other gastrointestinal irAEs has important implications for treatment.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1634\/theoncologist.2019-0083","type":"journal-article","created":{"date-parts":[[2019,11,6]],"date-time":"2019-11-06T19:39:12Z","timestamp":1573069152000},"page":"6-14","source":"Crossref","is-referenced-by-count":29,"title":["Diagnosis and Management of Rare Immune-Related Adverse Events"],"prefix":"10.1093","volume":"25","author":[{"given":"Sara R.","family":"Schoenfeld","sequence":"first","affiliation":[{"name":"Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary E.","family":"Aronow","sequence":"additional","affiliation":[{"name":"Retina Service, Massachusetts Eye and Ear, Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca Karp","family":"Leaf","sequence":"additional","affiliation":[{"name":"Division of Hematology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Dougan","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kerry L.","family":"Reynolds","sequence":"additional","affiliation":[{"name":"Division of Oncology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2019,11,6]]},"reference":[{"key":"2021122510022365400_R1","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"2021122510022365400_R2","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N Engl J Med"},{"key":"2021122510022365400_R3","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"key":"2021122510022365400_R4","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","article-title":"Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: A single-arm, multicentre, phase 2 trial","volume":"387","author":"Rosenberg","year":"2016","journal-title":"Lancet"},{"key":"2021122510022365400_R5","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/S1470-2045(16)30364-3","article-title":"Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: A multicentre, single-group, open-label","volume":"17","author":"Kaufman","year":"2016","journal-title":"phase 2 trial. Lancet Oncol"},{"key":"2021122510022365400_R6","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2017.2411","article-title":"Efficacy and safety of durvalumab in locally advanced or metastatic urothelial carcinoma: Updated results from a phase 1\/2 open-label study","volume":"3","author":"Powles","year":"2017","journal-title":"JAMA Oncol"},{"key":"2021122510022365400_R7","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1056\/NEJMoa1805131","article-title":"PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma","volume":"379","author":"Migden","year":"2018","journal-title":"N Engl J Med"},{"key":"2021122510022365400_R8","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","article-title":"Managing toxicities associated with immune checkpoint inhibitors: Consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group","volume":"5","author":"Puzanov","year":"2017","journal-title":"J Immunother Cancer"},{"key":"2021122510022365400_R9","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol"},{"issue":"suppl 4","key":"2021122510022365400_R10","doi-asserted-by":"crossref","first-page":"iv264","DOI":"10.1093\/annonc\/mdy162","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Haanen","year":"2018","journal-title":"Ann Oncol"},{"key":"2021122510022365400_R11","author":"International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH)"},{"key":"2021122510022365400_R12","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1080\/14737140.2017.1296765","article-title":"Immune-related ocular toxicities in solid tumor patients treated with immune checkpoint inhibitors: A systematic review","volume":"17","author":"Abdel-Rahman","year":"2017","journal-title":"Expert Rev Anticancer Ther"},{"key":"2021122510022365400_R13","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1097\/CCO.0000000000000296","article-title":"Ocular and orbital side-effects of checkpoint inhibitors: A review article","volume":"28","author":"Antoun","year":"2016","journal-title":"Curr Opin Oncol"},{"key":"2021122510022365400_R14","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1097\/IAE.0000000000002181","article-title":"Checkpoint inhibitor immune therapy: Systemic indications and ophthalmic side effects","volume":"38","author":"Dalvin","year":"2018","journal-title":"Retina"},{"key":"2021122510022365400_R15","article-title":"Immune retinopathy associated with nivolumab administration for metastatic non-small cell lung cancer","author":"Reddy","year":"2017","journal-title":"Retin Cases Brief Rep"},{"key":"2021122510022365400_R16","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/eye.2017.222","article-title":"Neuro-ophthalmic side effects of molecularly targeted cancer drugs","volume":"32","author":"Bhatti","year":"2018","journal-title":"Eye (Lond)"},{"key":"2021122510022365400_R17","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1159\/000455150","article-title":"Development of ocular rosacea following combined ipilimumab and nivolumab treatment for metastatic malignant skin melanoma","volume":"3","author":"Brouwer","year":"2017","journal-title":"Ocul Oncol Pathol"},{"key":"2021122510022365400_R18","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1186\/s12886-017-0611-3","article-title":"Bilateral uveitis and macular edema induced by nivolumab: A case report","volume":"17","author":"Theillac","year":"2017","journal-title":"BMC Ophthalmol"},{"key":"2021122510022365400_R19","first-page":"1183","article-title":"Bilateral uveitis associated with nivolumab therapy for metastatic melanoma: A case report","volume":"10","author":"Richardson","year":"2017","journal-title":"Int J Ophthalmol"},{"key":"2021122510022365400_R20","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1001\/jamaophthalmol.2018.0920","article-title":"Uveal effusion after immune checkpoint inhibitor therapy","volume":"136","author":"Thomas","year":"2018","journal-title":"JAMA Ophthalmol"},{"key":"2021122510022365400_R21","author":"National Cancer Institute","year":"2017"},{"key":"2021122510022365400_R22","doi-asserted-by":"crossref","first-page":"58709","DOI":"10.18632\/oncotarget.17634","article-title":"Ocular toxicities associated with targeted anticancer agents: An analysis of clinical data with management suggestions","volume":"8","author":"Fu","year":"2017","journal-title":"Oncotarget"},{"key":"2021122510022365400_R23","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.soncn.2017.08.003","article-title":"Cancer therapy with checkpoint inhibitors: Establishing a role for ophthalmology","volume":"33","author":"Davis","year":"2017","journal-title":"Semin Oncol Nurs"},{"key":"2021122510022365400_R24","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s40425-017-0210-0","article-title":"Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy","volume":"5","author":"Shiuan","year":"2017","journal-title":"J Immunother Cancer"},{"key":"2021122510022365400_R25","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.ctrc.2016.02.009","article-title":"Immune thrombocytopenia exacerbated by nivolumab in a patient with non-small-cell lung cancer","volume":"6","author":"Bagley Stephen","year":"2016","journal-title":"Cancer Treat Commun"},{"key":"2021122510022365400_R26","doi-asserted-by":"crossref","first-page":"4190","DOI":"10.1182\/blood-2010-08-302984","article-title":"The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia","volume":"117","author":"Neunert","year":"2011","journal-title":"Blood"},{"key":"2021122510022365400_R27","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S0140-6736(08)60203-2","article-title":"Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: A double-blind randomised controlled trial","volume":"371","author":"Kuter","year":"2008","journal-title":"Lancet"},{"key":"2021122510022365400_R28","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1634\/theoncologist.2018-0574","article-title":"Hematologic complications of immune checkpoint inhibitors","volume":"24","author":"Davis","year":"2019","journal-title":"The Oncologist"},{"key":"2021122510022365400_R29","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/j.1365-2141.2010.08412.x","article-title":"Pathophysiology and management of chronic immune thrombocytopenia: Focusing on what matters","volume":"152","author":"Toltl","year":"2011","journal-title":"Br J Haematol"},{"key":"2021122510022365400_R30","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0160221","article-title":"Adverse events associated with immune checkpoint blockade in patients with cancer: A systematic review of case reports","volume":"11","author":"Abdel-Wahab","year":"2016","journal-title":"PLoS One"},{"key":"2021122510022365400_R31","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.mayocp.2013.01.015","article-title":"Association between ipilimumab and celiac disease","volume":"88","author":"Gentile","year":"2013","journal-title":"Mayo Clin Proc"},{"key":"2021122510022365400_R32","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.gie.2017.04.033","article-title":"Acute hemorrhagic gastritis after nivolumab treatment","volume":"86","author":"Kobayashi","year":"2017","journal-title":"Gastrointest Endosc"},{"key":"2021122510022365400_R33","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.3389\/fimmu.2017.01547","article-title":"Checkpoint blockade toxicity and immune homeostasis in the gastrointestinal tract","volume":"8","author":"Dougan","year":"2017","journal-title":"Front Immunol"},{"key":"2021122510022365400_R34","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s40425-018-0396-9","article-title":"Fatal enteric plexus neuropathy after one dose of ipilimumab plus nivolumab: A case report","volume":"6","author":"Appelbaum","year":"2018","journal-title":"J Immunother Cancer"},{"key":"2021122510022365400_R35","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1038\/ajg.2013.79","article-title":"American College of Gastroenterology. ACG clinical guidelines: Diagnosis and management of celiac disease","volume":"108","author":"Rubio-Tapia","year":"2013","journal-title":"Am J Gastroenterol"},{"key":"2021122510022365400_R36","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1093\/annonc\/mdx306","article-title":"An unknown reaction to pembrolizumab: Giant cell arteritis","volume":"28","author":"Micaily","year":"2017","journal-title":"Ann Oncol"},{"key":"2021122510022365400_R37","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1002\/art.38282","article-title":"Drug-associated polymyalgia rheumatica\/giant cell arteritis occurring in two patients after treatment with ipilimumab, an antagonist of CTLA-4","volume":"66","author":"Goldstein","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"2021122510022365400_R38","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1136\/annrheumdis-2017-212257","article-title":"Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer-clinical aspects and relationship with tumour response: A single-centre prospective cohort study","volume":"77","author":"Kostine","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2021122510022365400_R39","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2017-000612","article-title":"Imaging in diagnosis, outcome prediction and monitoring of large vessel vasculitis: A systematic literature review and meta-analysis informing the EULAR recommendations","volume":"4","author":"Duftner","year":"2018","journal-title":"RMD Open"},{"key":"2021122510022365400_R40","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1148\/radiol.14140056","article-title":"Giant cell arteritis: Diagnostic accuracy of MR imaging of superficial cranial arteries in initial diagnosis-results from a multicenter trial","volume":"273","author":"Klink","year":"2014","journal-title":"Radiology"},{"key":"2021122510022365400_R41","doi-asserted-by":"crossref","first-page":"283","DOI":"10.2214\/ajr.184.1.01840283","article-title":"High-resolution MRI in giant cell arteritis: Imaging of the wall of the superficial temporal artery","volume":"184","author":"Bley","year":"2005","journal-title":"AJR Am J Roentgenol"},{"key":"2021122510022365400_R42","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1002\/acr.23177","article-title":"Rheumatic and musculoskeletal immune-related adverse events due to immune checkpoint inhibitors: A systematic review of the literature","volume":"69","author":"Cappelli","year":"2017","journal-title":"Arthritis Care Res (Hoboken)."},{"key":"2021122510022365400_R43","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1007\/s10067-018-4177-0","article-title":"Vasculitis associated with immune checkpoint inhibitors - a systematic review","volume":"37","author":"Daxini","year":"2018","journal-title":"Clin Rheumatol"},{"key":"2021122510022365400_R44","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.jdcr.2018.05.020","article-title":"Checkpoint inhibitor-associated cutaneous small vessel vasculitis","volume":"4","author":"Castillo","year":"2018","journal-title":"JAAD Case Rep"},{"key":"2021122510022365400_R45","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1093\/annonc\/mdw613","article-title":"Vasculitic neuropathy induced by pembrolizumab","volume":"28","author":"Aya","year":"2017","journal-title":"Ann Oncol"},{"key":"2021122510022365400_R46","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2017-221852","article-title":"Aftermath of induced inflammation: Acute periaortitis due to nivolumab therapy","author":"Roy","year":"2017","journal-title":"BMJ Case Rep"},{"key":"2021122510022365400_R47","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/S1470-2045(16)30126-7","article-title":"Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): An open-label, randomised","volume":"17","author":"Weber","year":"2016","journal-title":"phase 2 trial. Lancet Oncol"},{"key":"2021122510022365400_R48","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"2021122510022365400_R49","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"key":"2021122510022365400_R50","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1001\/jamadermatol.2014.2233","article-title":"Drug-associated dermatomyositis following ipilimumab therapy: A novel immune-mediated adverse event associated with cytotoxic T-lymphocyte antigen 4 blockade","volume":"151","author":"Sheik Ali","year":"2015","journal-title":"JAMA Dermatol"},{"key":"2021122510022365400_R51","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1016\/j.mayocp.2017.03.016","article-title":"Scleroderma induced by pembrolizumab: A case series","volume":"92","author":"Barbosa","year":"2017","journal-title":"Mayo Clin Proc"},{"key":"2021122510022365400_R52","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMc0904283","article-title":"Anti-CTLA4 antibody-induced lupus nephritis","volume":"361","author":"Fadel","year":"2009","journal-title":"N Engl J Med"},{"key":"2021122510022365400_R53","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1097\/CJI.0000000000000196","article-title":"PD-1 inhibitor-associated myopathies: Emerging immune-mediated myopathies","volume":"41","author":"Liewluck","year":"2018","journal-title":"J Immunother"},{"key":"2021122510022365400_R54","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1111\/1756-185X.13076","article-title":"Immunotherapy-induced sarcoidosis in patients with melanoma treated with PD-1 checkpoint inhibitors: Case series and immunophenotypic analysis","volume":"20","author":"Lomax","year":"2017","journal-title":"Int J Rheum Dis"},{"key":"2021122510022365400_R55","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1097\/CJI.0000000000000181","article-title":"Sarcoidosis following anti-PD-1 and anti-CTLA-4 therapy for metastatic melanoma","volume":"40","author":"Reddy","year":"2017","journal-title":"J Immunother"},{"key":"2021122510022365400_R56","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1001\/jama.287.1.92","article-title":"Does this patient have temporal arteritis?","volume":"287","author":"Smetana","year":"2002","journal-title":"JAMA"},{"key":"2021122510022365400_R57","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1136\/bjo.86.5.530","article-title":"Effect of prior steroid treatment on temporal artery biopsy findings in giant cell arteritis","volume":"86","author":"Ray-Chaudhuri","year":"2002","journal-title":"Br J Ophthalmol"},{"key":"2021122510022365400_R58","doi-asserted-by":"crossref","first-page":"987","DOI":"10.7326\/0003-4819-120-12-199406150-00003","article-title":"How does previous corticosteroid treatment affect the biopsy findings in giant cell (temporal) arteritis?","volume":"120","author":"Achkar","year":"1994","journal-title":"Ann Intern Med"},{"key":"2021122510022365400_R59","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.semarthrit.2006.12.005","article-title":"Influence of previous corticosteroid therapy on temporal artery biopsy yield in giant cell arteritis","volume":"37","author":"Narv\u00e1ez","year":"2007","journal-title":"Semin Arthritis Rheum"},{"key":"2021122510022365400_R60","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1056\/NEJMoa1613849","article-title":"Trial of tocilizumab in giant-cell arteritis","volume":"377","author":"Stone","year":"2017","journal-title":"N Engl J Med"},{"key":"2021122510022365400_R61","doi-asserted-by":"crossref","first-page":"H1052","DOI":"10.1152\/ajpheart.00024.2017","article-title":"Immune checkpoint dysfunction in large and medium vessel vasculitis","volume":"312","author":"Watanabe","year":"2017","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"2021122510022365400_R62","doi-asserted-by":"crossref","first-page":"E970","DOI":"10.1073\/pnas.1616848114","article-title":"Immunoinhibitory checkpoint deficiency in medium and large vessel vasculitis","volume":"114","author":"Zhang","year":"2017","journal-title":"Proc Natl Acad Sci USA"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2019-0083","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2019-0083","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/25\/1\/6\/41919413\/oncolo_25_1_6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/25\/1\/6\/41919413\/oncolo_25_1_6.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,25]],"date-time":"2021-12-25T10:04:06Z","timestamp":1640426646000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/25\/1\/6\/6443335"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,6]]},"references-count":62,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,11,6]]},"published-print":{"date-parts":[[2020,1,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2019-0083","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,1,1]]},"published":{"date-parts":[[2019,11,6]]}}}